新型头孢布丁-阿维巴坦、头孢他啶-阿维巴坦和比较物对美国门诊中心和养老院肠杆菌挑战组的活性（2022-2024）。

IF 4.1 2区医学 Q2 MICROBIOLOGY

Antimicrobial Agents and Chemotherapy Pub Date : 2025-04-03 DOI:10.1128/aac.01867-24

Aliaa Fouad, April M Bobenchik, Robin Chamberland, Andrew E Clark, Holly K Huse, Isabella W Martin, A Brian Mochon, Erik Munson, Maroun M Sfeir, Monica Srodon, Kimberly Taylor, Yungchou Wang, Lars F Westblade, David P Nicolau, Tomefa E Asempa

{"title":"新型头孢布丁-阿维巴坦、头孢他啶-阿维巴坦和比较物对美国门诊中心和养老院肠杆菌挑战组的活性（2022-2024）。","authors":"Aliaa Fouad, April M Bobenchik, Robin Chamberland, Andrew E Clark, Holly K Huse, Isabella W Martin, A Brian Mochon, Erik Munson, Maroun M Sfeir, Monica Srodon, Kimberly Taylor, Yungchou Wang, Lars F Westblade, David P Nicolau, Tomefa E Asempa","doi":"10.1128/aac.01867-24","DOIUrl":null,"url":null,"abstract":"Ceftibuten is being developed in combination with the oral prodrug of avibactam. Outpatient isolates (n = 500) from 11 US states underwent susceptibility testing with manual broth microdilution. Ceftibuten had susceptibility rates of 64% (CLSI) and 23% (EUCAST). Ceftibuten-avibactam achieved 96.4% inhibition at MIC ≤ 1 µg/mL. Susceptibility rates were as follows: cefpodoxime (2.6%), ceftriaxone (1%), ceftazidime-avibactam (99.6%), tebipenem (89%), ertapenem (94.4%), levofloxacin (26.6%), trimethoprim-sulfamethoxazole (40.2%), and fosfomycin (96.8%). Ceftibuten-avibactam demonstrates potent in vitro activity against cephalosporin non-susceptible isolates.","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0186724"},"PeriodicalIF":4.1000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of Enterobacterales from outpatient centers and nursing homes across the United States (2022-2024).\",\"authors\":\"Aliaa Fouad, April M Bobenchik, Robin Chamberland, Andrew E Clark, Holly K Huse, Isabella W Martin, A Brian Mochon, Erik Munson, Maroun M Sfeir, Monica Srodon, Kimberly Taylor, Yungchou Wang, Lars F Westblade, David P Nicolau, Tomefa E Asempa\",\"doi\":\"10.1128/aac.01867-24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Ceftibuten is being developed in combination with the oral prodrug of avibactam. Outpatient isolates (n = 500) from 11 US states underwent susceptibility testing with manual broth microdilution. Ceftibuten had susceptibility rates of 64% (CLSI) and 23% (EUCAST). Ceftibuten-avibactam achieved 96.4% inhibition at MIC ≤ 1 µg/mL. Susceptibility rates were as follows: cefpodoxime (2.6%), ceftriaxone (1%), ceftazidime-avibactam (99.6%), tebipenem (89%), ertapenem (94.4%), levofloxacin (26.6%), trimethoprim-sulfamethoxazole (40.2%), and fosfomycin (96.8%). Ceftibuten-avibactam demonstrates potent in vitro activity against cephalosporin non-susceptible isolates.\",\"PeriodicalId\":8152,\"journal\":{\"name\":\"Antimicrobial Agents and Chemotherapy\",\"volume\":\" \",\"pages\":\"e0186724\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2025-04-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antimicrobial Agents and Chemotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1128/aac.01867-24\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antimicrobial Agents and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1128/aac.01867-24","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

头孢布滕正在与口服前药阿维巴坦联合开发。美国11个州门诊分离株（n = 500）采用手工肉汤微量稀释进行药敏试验。头孢布烯的易感性分别为64% （CLSI）和23% （EUCAST）。头孢布丁-阿维巴坦在MIC≤1µg/mL时的抑制率为96.4%。易感率依次为：头孢多肟（2.6%）、头孢曲松（1%）、头孢他啶-阿维巴坦（99.6%）、替比培南（89%）、厄他培南（94.4%）、左氧氟沙星（26.6%）、甲氧苄啶-磺胺甲恶唑（40.2%）、磷霉素（96.8%）。头孢布丁-阿维巴坦对头孢菌素不敏感的分离株具有有效的体外活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of Enterobacterales from outpatient centers and nursing homes across the United States (2022-2024).

Ceftibuten is being developed in combination with the oral prodrug of avibactam. Outpatient isolates (n = 500) from 11 US states underwent susceptibility testing with manual broth microdilution. Ceftibuten had susceptibility rates of 64% (CLSI) and 23% (EUCAST). Ceftibuten-avibactam achieved 96.4% inhibition at MIC ≤ 1 µg/mL. Susceptibility rates were as follows: cefpodoxime (2.6%), ceftriaxone (1%), ceftazidime-avibactam (99.6%), tebipenem (89%), ertapenem (94.4%), levofloxacin (26.6%), trimethoprim-sulfamethoxazole (40.2%), and fosfomycin (96.8%). Ceftibuten-avibactam demonstrates potent in vitro activity against cephalosporin non-susceptible isolates.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Antimicrobial Agents and Chemotherapy 医学-微生物学

CiteScore

10.00

自引率

8.20%

发文量

762

审稿时长

3 months

期刊介绍： Antimicrobial Agents and Chemotherapy (AAC) features interdisciplinary studies that build our understanding of the underlying mechanisms and therapeutic applications of antimicrobial and antiparasitic agents and chemotherapy.